| Code | 9688D | ||||||||||
| MA number | 44/0038/22-S | ||||||||||
| Product Form: | tbl flm 60(2x30)x400 mg (blis.Al/PVC/PE/PVDC-multibal.) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Teva B.V., Netherland | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | blister Al/PVC/PE/PVDC | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 28.02.2022 |
| Validity: | 28.02.2027 |
| Pediatric warnings: | Yes |
| PIL: |
PIL_Pazopanib Teva 02_2022.pdf
|
| SPC: |
SPC_Pazopanib Teva 400 mg filmom obalené tablety_04.2023.pdf
|
| Safety feature | Yes |
| Data update: | 14.04.2023 |
